Sarran, Christophe
Halpin, David
Levy, Mark L
Prigmore, Samantha
Sachon, Patrick
Article History
Received: 10 February 2014
Revised: 1 August 2014
Accepted: 31 August 2014
First Online: 23 October 2014
Competing interests
: This evaluation was funded and conducted by the Met Office. Professor Halpin chaired the Met Office’s COPD Advisory Group. MLL has accepted sponsorship from GlaxoSmithKline (GSK), AstraZeneca (AZ), Boehringer Ingelheim (BI), Chiesi, Merck Sharpe and Dohme (MSD), Merck, Altana Pharma, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, Napp Pharmaceuticals, TEVA and Schering Plough for attending conferences. He has accepted lecture fees from BI, GSK, AZ, Chiesi, TEVA and Alk-Abello. He has been on advisory boards or provided consultancy for GSK, Schering Plough, MSD, Chiesi, Altana Pharma, Ranbaxy, AZ, Clement Clarke International, National Services for Health Improvement (NSHI) and Novartis. He has had research grants from BI, Pfizer and GSK. He is a member of The Aerosol Drug Management Improvement Team (ADMIT), which is supported by an unrestricted educational grant from Consorzio Ferrara Ricerche. Mark L. Levy is the Editor Emeritus of the PCRJ, but was not involved in the editorial review of, nor the decision to publish, this article. The remaining authors declare no conflict of interest.